P
Paul H. M. Savelkoul
Researcher at Maastricht University
Publications - 253
Citations - 12176
Paul H. M. Savelkoul is an academic researcher from Maastricht University. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 52, co-authored 233 publications receiving 10186 citations. Previous affiliations of Paul H. M. Savelkoul include Vanderbilt University Medical Center & University of Amsterdam.
Papers
More filters
Journal ArticleDOI
Workload, diagnostic work-up and treatment of urinary tract infections in adults during out-of-hours primary care: a retrospective cohort study.
TL;DR: It is found that correctly diagnosing UTIs and prescribing antibiotics for UTIs is a challenge that needs major improvement, especially during out-of-hours GP care.
Journal ArticleDOI
Rapid screening by real-time 16S rDNA PCR for bacterial contamination of blood products
TL;DR: Real-time polymerase chain reaction (PCR) with particular focus on real-time 16S rDNA detection, will be discussed in this review, for detection of bacterial contamination in platelet concentrates.
Journal ArticleDOI
Rapid plasmid replicon typing by real time PCR melting curve analysis
TL;DR: This real-time melting curve replicon typing method appears to be fast, sensitive, less laborious, less prone to contamination and applicable in a routine laboratory environment.
Journal ArticleDOI
Extended-spectrum beta-lactamase producing Enterobacteriaceae (ESBL-E) isolated from bean sprouts in the Netherlands
Pepijn Huizinga,Pepijn Huizinga,Eefje J. A. Schrauwen,Silvia García-Cobos,Ina Willemsen,Ina Willemsen,Carlo Verhulst,Alexander W. Friedrich,Paul H. M. Savelkoul,Paul H. M. Savelkoul,John W. A. Rossen,Jan Kluytmans +11 more
TL;DR: In conclusion, bean sprouts frequently harbor ESBL-E, which is a potential source for consumers, and isolates from samples closely matched in time were frequently clonally related, indicative of batch contamination.
Journal ArticleDOI
Safety and immunogenicity of HBAI20 Hepatitis B vaccine in healthy naïve and nonresponding adults.
Özgür M Koc,Özgür M Koc,Paul H. M. Savelkoul,Paul H. M. Savelkoul,I. H. M. van Loo,Anna Peeters,A. M. L. Oude Lashof +6 more
TL;DR: The HBAI20 vaccine was able to elicit protective anti‐HBs titres in 90% of nonresponders, 1 month after the third vaccination, and may promote more rapid protection against hepatitis B infection.